Home › Coronary Artery Disease › Michigan › Lansing
Coronary Artery Disease clinical trials in Lansing, MI
3 studies for Coronary Artery Disease are looking for participants at sites in and around Lansing (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RecruitingPhase 4
- McLaren Center for Research and Innovation, Lansing
- UMH-Sparrow Clinical Research Institute, Lansing
Product Surveillance Registry
RecruitingObservational study
- Lansing, Lansing
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
Recruiting
- Sparrow Clinical Research Institute, Lansing
About Coronary Artery Disease
Coronary artery disease (CAD) is the most common type of heart disease. It can lead to angina and heart attack. Read about symptoms and tests.
More about Coronary Artery Disease on MedlinePlus
Coronary Artery Disease trials in other cities
- New York City, NY20 studies
- Dallas, TX16 studies
- Boston, MA16 studies
- Atlanta, GA16 studies
- Minneapolis, MN15 studies
- Jacksonville, FL12 studies
- Cleveland, OH12 studies
- Nashville, TN11 studies
- Durham, NC9 studies
- Columbus, OH9 studies
- Plano, TX9 studies
- Philadelphia, PA9 studies
Other studies in Lansing
- Lung Cancer12 studies
- Prostate Cancer10 studies
- Non-Small Cell Lung Cancer10 studies
- Breast Cancer10 studies
- Cancer (all types)6 studies
- Disorders of Excessive Somnolence6 studies
- Sleep Disorders5 studies
- Bladder Cancer5 studies
- Laryngeal Cancer5 studies
- Ovarian Cancer4 studies
- Multiple Myeloma4 studies
- Narcolepsy4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.